Table 1.
Baseline characteristics of current and ex-smokers in the CORTICO-COP trial.
| All Current Smokers | Current Smokers Control Group | Current Smokers Eosinophil-Guided Group | All Ex-Smokers | Ex-Smokers Control Group | Ex-Smokers Eosinophil-Guided Group | |
|---|---|---|---|---|---|---|
| Number, n (%) | 104 (100) | 50 (100) | 54 (100) | 208 (100) | 105 (100) | 103 (100) |
| Age, median (IQR), years | 72 (66–78) | 73 (66–78) | 70 (66–77) | 76 (71–83) | 76 (71–83) | 77 (72–83) |
| Male sex, n (%) | 47 (45) | 20 (40) | 27 (50) | 94 (45) | 48 (46) | 46 (45) |
| BMI, median (IQR), kg/m2 | 23.2 (20.0–27.7) | 21.9 (19.3–27.5) | 23.7 (20.6–27.5) | 24.2 (20,8–27.4) | 24.4 (20.8–27.9) | 24.2 (20.8–26.3) |
| Pack-years history of current or prior smoker (median, IQR), years |
50 (40–60) | 50 (40–60) | 50 (40–60) | 40 (30–50) | 45 (30–50) | 40 (28–50) |
| Blood eosinophil count, median (IQR), ×109 cells/L |
0.09 (0.01–0.20) | 0.07 (0.01–0.15) | 0.10 (0.01–0.29) | 0.07 (0.01–0.27) | 0.06 (0.01–0.23) | 0.10 (0.01–0.30) |
| FEV1, median (IQR), % | 32 (23–40) | 30 (22–40) | 32 (25–39) | 30 (23–39) | 30 (24–40) | 30 (23–38) |
| CAT scores | 23 (18–27) | 21 (18–27) | 23 (18–28) | 21 (16–25) | 21 (14–25) | 21 (17–25) |
| MRC, median (IQR) | 4 (3–5) | 4 (3–5) | 4 (3–5) | 4 (3–5) | 4 (3–4) | 4 (3–5) |
| MRC 1, n (%) | 3 (3) | 0 (0) | 3 (6) | 5 (2) | 3 (3) | 2 (2) |
| MRC 2, n (%) | 9 (9) | 4 (8) | 5 (10) | 14 (7) | 5 (5) | 9 (9) |
| MRC 3, n (%) | 26 (25) | 16 (32) | 10 (19) | 64 (31) | 34 (33) | 30 (30) |
| MRC 4, n (%) | 30 (29) | 11 (22) | 19 (37) | 69 (34) | 39 (38) | 30 (30) |
| MRC 5, n (%) | 34 (33) | 19 (38) | 15 (29) | 52 (25) | 23 (22) | 29 (29) |
| Treatment with LABA alone, n (%) | 19 (18) | 7 (14) | 12 (22) | 65 (31) | 26 (25) | 39 (38) |
| Treatment with LAMA alone, n (%) | 9 (9) | 4 (8) | 5 (9) | 20 (10) | 15 (14) | 5 (5) |
| Treatment with ICS alone, n (%) | 5 (5) | 2 (4) | 3 (6) | 4 (2) | 1 (1) | 3 (3) |
| Treatment with ICS/LABA, n (%) | 58 (56) | 31 (62) | 27 (50) | 106 (51) | 60 (57) | 46 (45) |
| None of the above, n (%) | 13 (12) | 6 (12) | 7 (13) | 13 (6) | 3 (3) | 10 (10) |
| 0 severe exacerbations 12 months prior to baseline, n (%) | 72 (69) | 35 (70) | 37 (69) | 136 (65) | 68 (65) | 68 (66) |
| 1 severe exacerbation 12 months prior to baseline, n (%) | 17 (16) | 8 (16) | 9 (17) | 41 (20) | 20 (19) | 21 (20) |
| ≥2 severe exacerbations 12 months prior to baseline, n (%) | 15 (14) | 7 (14) | 8 (15) | 31 (15) | 17 (16) | 14 (14) |
| Ischaemic heart disease, n (%) | 15 (14) | 8 (16) | 7 (13) | 21 (10) | 6 (6) | 15 (15) |
| Hypertension, n (%) | 39 (38) | 18 (36) | 21 (39) | 82 (39) | 41 (39) | 41 (40) |
| Hypercholesterolemia, n (%) | 15 (14) | 10 (20) | 5 (9) | 22 (11) | 9 (9) | 13 (13) |
| Chronic renal failure, n (%) | 2 (2) | 2 (4) | 0 (0) | 19 (9) | 7 (7) | 12 (12) |
| Heart failure, n (%) | 6 (6) | 4 (8) | 2 (4) | 24 (12) | 9 (9) | 15 (15) |
| Osteoporosis, n (%) | 18 (17) | 9 (18) | 9 (17) | 39 (19) | 15 (14) | 24 (23) |
Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroids; IQR, interquartile range; LABAs, long-acting beta-2 agonists; LAMAs, long-acting muscarinic antagonists; MRC, Medical Research Council Dyspnoea Scale.